logo
ProjectEnded

Targeting B cell Activation driven by Natural Killer cells

One of 10,000+ projects Taiyo tracks in France.

Source: EU Funding & Tenders Portal

Autoimmune diseases affect nearly 4% of the world’s population and can be life-threatening. Among them, primary Sjögren Syndrome (pSS) is the most common systemic autoimmune disease. Unfortunately, to date, treatments are focusing on relieving symptoms. It is of public relevance to find potential new biomarkers for treatments. B cells are one key player in pSS and promising drugs targeting B cell

Status
Closed
Sector
Education
Location
France
Updated
22 Jul 2026
Source
EU Funding & Tenders Portal

ConstructChat

Ask ConstructChat about Targeting B cell Activation driven by Natural Killer cells

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

3 Q
The project “Targeting B cell Activation driven by Natural Killer cells” is an infrastructure initiative in the Education sector, located in France. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Participants

Not available for this record.

Status

Original status

ended

Taiyo status

Closed

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

Autoimmune diseases affect nearly 4% of the world’s population and can be life-threatening. Among them, primary Sjögren Syndrome (pSS) is the most common systemic autoimmune disease. Unfortunately, to date, treatments are focusing on relieving symptoms. It is of public relevance to find potential new biomarkers for treatments. B cells are one key player in pSS and promising drugs targeting B cell activation are currently under phase 3 clinical trials. Restraining B cell hyperactivity is central to treating pSS permanently. Hence, instead of targeting B cell activation, pSS treatments would also benefit from targeting signals or interactions leading to B cell activation. The TABANK project aims to address this hypothesis by using cutting-edge technologies (high-parameter flow cytometry, single-cell sequencing technologies and unsupervised analysis) to interrogate the immune network in the circulation of pSS donors as well as in the inflamed environment of impaired salivary glands. This overarching goal will be achieved by (i) Compiling a comprehensive database of immune cell profiles in pSS using both single-cell sequencing and high-parameter mass and flow cytometry; (ii) Determining potential interactions of immune cells leading to B cell activation using a novel computational approach; and (iii) Validating these interactions using ex vivo culture. TABANK will be conducted at the Lymphocytes B, Autoimmunity and Immunotherapies center, Université of Brest Occidentale a leading research institution in the study of immunotherapies for B cell diseases. This project will be supervised by two leading experts in autoimmune diseases and B cell biology. This unique synergy, in addition the researcher’s own expertise in examining immune responses in human tissues, particularly oral mucosal tissues, will precondition the project for success while facilitating a mutually beneficial, two-way transfer of knowledge.

Location

Country

France

Source

Source

EU Funding & Tenders Portal

URL

More Details

Record type

Project

Sector

Education

Article published date

2025-10-15

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project